Dplo (DPLO) 36.71 $DPLO Diplomat Pharmacy: A Secular

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 10:55 AM

Dplo (DPLO) 36.71 $DPLO

Diplomat Pharmacy: A Secular Bull Story Powered By The Analyst Catalyst
Dallas Salazar - at Seeking Alpha - Fri Apr 24, 7:10AM CDT

DPLO: 36.71 (+0.46)

GE Capital enters into USD320m credit facility with Diplomat Pharmacy
M2 - Fri Apr 24, 5:06AM CDT
GE Capital said on Thursday that its Healthcare Financial Services business has signed a USD320m senior secured credit facility with Diplomat Pharmacy (NYSE

PLO).
DPLO: 36.71 (+0.46)

GE Capital Provides $320 Million Credit Facility to Diplomat Pharmacy, Includes Funds for Acquisition of BioRx
M2 - Thu Apr 23, 10:52AM CDT
GE Capital's Healthcare Financial Services (HFS) business announced today that it has provided a $320 million senior secured credit facility to Diplomat Pharmacy, Inc., the country's largest independent specialty pharmacy. GE Capital Markets was lead arranger and bookrunner on the transaction.
GE: 26.80 (-0.05), DPLO: 36.71 (+0.46)

Diplomat to Release First Quarter Operating Results and Host Conference Call on Monday, May 11, 2015
PR Newswire - Wed Apr 22, 3:01PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, will release its first quarter operating results on Monday, May 11, 2015 after market close, with a conference call to follow at 5:00p.m. Eastern Time.
DPLO: 36.71 (+0.46)

Diplomat Launches National Search for Internship and Fellowship in Flint
PR Newswire - Fri Apr 17, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced that it is seeking applicants for their annual Internship and Fellowship programs for the summer of 2015.
DPLO: 36.71 (+0.46)

Diplomat elects Shannon M. Beltrand as new CISO
M2 - Fri Apr 17, 6:05AM CDT
Pharmacy company Diplomat Pharmacy (NYSE

PLO) revealed on Thursday the appointment of Shannon Beltrand as its chief information security officer.
DPLO: 36.71 (+0.46)

Diplomat Names Shannon M. Beltrand as New CISO
PR Newswire - Thu Apr 16, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced the addition of Shannon Beltrand to their senior leadership team as chief information security officer. In this role, Beltrand will be responsible for securing and properly monitoring Diplomat's data, systems and facilities to ensure that Diplomat is secure both internally and externally. Additionally, she will play key roles in systems auditing and business continuity planning.
DPLO: 36.71 (+0.46)

Diplomat to Dispense Novartis Drug, JADENU(TM)
PR Newswire - Mon Apr 13, 3:48PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) to distribute JADENU(TM), a drug recently approved by the U.S. Food and Drug Administration to treat patients with chronic iron overload.
DPLO: 36.71 (+0.46), NVS: 104.28 (-1.22)

Retail ETFs Soar to New Highs Despite Slump in Retail Sales
at The Street - Mon Apr 13, 6:10AM CDT
Should investors be worried about a growing disconnect between record-high retail ETF prices and slumping retail sales? Retail sales data, out Tuesday, has fallen for the past 3 months.
AMZN: 445.10 (+55.11), HD: 113.70 (-0.26), KR: 71.70 (+0.77), MCK: 229.20 (+0.09), CAH: 91.38 (-0.12), DPLO: 36.71 (+0.46), WMT: 79.84 (+0.66), RTH: 77.90 (+1.12), FIVE: 36.04 (+0.10), XRT: 100.98 (+0.18), KMX: 69.97 (-0.75), WBA: 85.98 (-0.71), CONN: 30.85 (+0.15), JCP: 8.41 (-0.07), COST: 148.12 (+0.82), CVS: 101.58 (+0.70)

BioScrip (BIOS) in Focus: Stock Adds 5.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 8:25AM CDT
BioScrip (BIOS) was a big mover last session, with shares rising over 5% on the day.
DPLO: 36.71 (+0.46), BIOS: 5.26 (+0.01)

Diplomat Celebrates 40th Anniversary
PR Newswire - Fri Apr 03, 7:58AM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) is celebrating 40 years of providing quality pharmacy services to its patients nationwide.
DPLO: 36.71 (+0.46)

Diplomat Completes Acquisition of BioRx
PR Newswire - Wed Apr 01, 4:06PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), announced today it has completed the acquisition of BioRx, LLC, a highly specialized pharmacy and infusion services company that provides treatments for patients with ultra-orphan and rare, chronic diseases based in Cincinnati, Ohio. With the close of this acquisition, the combined resources and capabilities will make Diplomat one of the nation's largest specialty infusion providers.
DPLO: 36.71 (+0.46)

Diplomat announces closing of follow-on public offering and full exercise of option by underwriters
PR Newswire - Tue Mar 31, 1:12PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced today the closing of its follow-on public offering of 9,821,125 shares of common stock at a price to the public of $29.00 per share, which included 1,281,016 shares sold pursuant to the full exercise of the underwriters' option. Diplomat sold 6,821,125 shares of common stock and certain shareholders of Diplomat sold 3,000,000 shares of common stock. Diplomat will not receive any proceeds from shares of common stock sold by the selling shareholders.
DPLO: 36.71 (+0.46)

InsiderInsights.com Daily Round Up 3/27/15: COCP, GPRO, SJW, AGCO
InsiderInsights - at Seeking Alpha - Sun Mar 29, 12:55PM CDT

GPRO: 44.73 (-1.35), HCOM: 26.37 (-0.03), DPLO: 36.71 (+0.46), AGCO: 48.31 (-0.56), ENV: 54.31 (-0.22), LPI: 14.72 (-0.32), GOOG: 565.06 (+18.06), NOW: 76.09 (-0.79), ARMK: 31.66 (+0.20), JAZZ: 189.42 (+0.33), GLF: 13.58 (-0.05), SJW: 30.41 (+0.43), JGW: 10.58 (-0.03), ALCO: 47.11 (-0.65), FI: 18.80 (-0.36), CRM: 67.83 (-0.64)

Diplomat Pharmacy
at Investor's Business Daily - Thu Mar 26, 5:32PM CDT
Diplomat Pharmacy (DPLO) shares surged 14.1% to 34.63 one day after the nation's largest independent specialty pharmacy on Wed. announced pricing of its follow-on 8.54 mil share public offering at $29 per share. Diplomat is selling 5.54 mil shares,...
DPLO: 36.71 (+0.46)

Why Diplomat Pharmacy Inc. Is Soaring Higher Today.
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 26, 12:50PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Source: Diplomat Pharmacy, What: Shares...
ESRX: 87.34 (+0.45), DPLO: 36.71 (+0.46), CVS: 101.58 (+0.70)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 11:49AM CDT

TRVN: 6.69 (-0.30), WGO: 21.06 (+0.29), CCSC: 5.42 (-0.15), OTIV: 1.50 (-0.10), DPLO: 36.71 (+0.46), CNAT: 6.66 (-0.15), WGBS: 4.62 (+0.05), HKTV: 9.11 (+1.44), DVD: 2.39 (-0.02), SEDG: 24.89 (+0.10), ENVA: 19.33 (-0.33), SEED: 1.77 (+0.16), RHT: 76.83 (-0.02), SCMP: 21.09 (-0.31), SGNT: 25.20 (-0.40), WRLD: 74.78 (-0.56), VBLT: 4.23 (+0.07), RCON: 1.90 (-0.10), SNDK: 67.92 (-0.84)

Diplomat Pharmacy (DPLO) Stock Surges Today After Pricing Public Offering
at The Street - Thu Mar 26, 11:19AM CDT
Shares of Diplomat Pharmacy (DPLO) are up after the company announced the pricing of its follow-on public offering of 8,540,109 shares at $29 per share.
DPLO: 36.71 (+0.46)

Diplomat announces pricing of follow-on public offering of common stock
PR Newswire - Wed Mar 25, 8:00PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced today the pricing of its follow-on public offering of 8,540,109 shares of common stock at a price to the public of $29.00 per share. Diplomat is selling 5,540,109 shares of common stock and certain shareholders of Diplomat are selling 3,000,000 shares of common stock. The Company has granted the underwriters a 30-day option to purchase up to an additional 1,281,016 shares of common stock. Diplomat will not receive any proceeds from shares of common stock sold by the selling shareholders.
DPLO: 36.71 (+0.46)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hollywood Vampires' Limited Art Sparks Las Vegas Buzz

A Collaboration to Captivate Art and Rock Enthusiasts When it comes to mixing rock and roll with fine art, Markus Klinko's exclusive photograph featuring the Hollywood Vampires hits the nail on the head. It’s not just an image; it’s a slice of modern rock history immortalized on paper. This new release, a portrait capturing the raw passion of Alice Cooper, Johnny...

Jacobi's Harness Brings AI from Concept to Reality

The Challenge of Moving AI to Production Diving headfirst into AI in finance? Well, Jacobi's bold move with their new toy, the Investment Management Harness, spotlights a filthy secret: the hurdles between a big idea and execution are seldom technological. We got AI shaving prototyping time down to just days, yet pushing to production? That's a marathon in itself. Boards...

Innovative Trial Targets Drug Resistance in Lung Cancer

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Cavli360 Unites Global IoT Voices in New Magazine

Connecting IoT Insights: A Fresh Spin on Industry Collaboration Alright, stepping away from stocks and straight into tech talk—Cavli Wireless just dropped their shiny new industry mag, Cavli360, aiming to be a voice hub for all things IoT. This ain't just another glossy promo piece; it's a rallying cry to bring together the brains across the nets and fibers shaping our...

Enertech's New Moves Aim to Make Geothermal Mainstream

Breaking Through Financial Barriers in Geothermal Energy Finally, we're seeing some real movement in the geothermal heat pump sector. The longtime hurdles that kept ground-sourced heating and cooling tech at arm's length from the everyday homeowner are starting to tumble, thanks to Enertech Global's latest initiatives. Enertech's Double Deal: A New Lease on Geothermal...

Sony's LYTIA 720 Image Sensor: A Game Changer?

Unpacking Sony's Latest Sensor: LYTIA 720 Tell me, when was the last time a tech drop made you shake your head in awe? Sony just pulled one of those moves with their latest toy, the LYTIA 720. We're talking a 50-effective megapixel CMOS image sensor crafted for mobile warriors, and it packs a punch that should have the competition looking over their shoulder. Dazzling...

OppFi's Q3 2026: Is Their Growth Strategy on Track?

OppFi's Third Quarter Performance Unpacked OppFi's recent third-quarter disclosures should get investors pondering. They've launched a new line of credit product, plugging a gap in their service portfolio, and aimed to widen their customer net. Their targeted share repurchase of $6.7 million in stock isn't small potatoes either, showing a vote of confidence in their own...

Seasonal Hiring Booms as Firms Eye Long-Term Talent

A Strategic Shift in Seasonal Hiring It ain't just about the holiday rush anymore, folks. Companies are waking up to the idea that seasonal gigs are more than a temporary Band-Aid. This year, nearly 2 out of 5 companies are planning to bring more seasonal folks into the fold compared to last year. That means a good dose of them are looking for longer-term value—like...

Montage Partners Maintains its Founder-Friendly Status

A Streak That Speaks Volumes Did you catch the latest from Scottsdale? Montage Partners, that people-first private equity outfit, just notched its sixth straight year on Inc.'s Founder-Friendly Investors list. Not something you snag with a casual handshake or flimsy promises—this accolade is about real, boots-on-the-ground partnership. Apparently, 294 firms made the...

Psoriasis Shines Spotlight on Stigma in 2026 Campaign

Peeling Back the Layers of Stigma On World Psoriasis Day, we're flipping the script from pity parties to real change. IFPA's 'Look Beyond My Skin' campaign is rallying against the stigma choking young folks with psoriasis. You can't deny the massive size of this issue – over 100 million people wrangle with this condition globally. Yet, as many of these warriors are...